Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- 37 Institutional Review Boards and Oversight of Alzheimer’s Disease Trials
- 38 SPARKing Drug Development for Alzheimer’s Disease in Academia
- 39 The Role of Professional Associations and Patient Advocacy in Advancing Alzheimer’s Drug Development
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- Index
39 - The Role of Professional Associations and Patient Advocacy in Advancing Alzheimer’s Drug Development
from Section 5 - Academic Drug-Development Programs
Published online by Cambridge University Press: 03 March 2022
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- 37 Institutional Review Boards and Oversight of Alzheimer’s Disease Trials
- 38 SPARKing Drug Development for Alzheimer’s Disease in Academia
- 39 The Role of Professional Associations and Patient Advocacy in Advancing Alzheimer’s Drug Development
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- Index
Summary
Drug development teams once focused on study design and company priorities, must now expand their efforts to include the professional, patient, and policy advocacy landscape. These groups are essential to setting research and policy priorities and are influential voices in securing funding at the federal, state, and private investment levels, as well as input to optimize the probability of success of clinical development programs. Professional associations and patient advocacy groups also enable collaboration across industry to address challenges that require resources beyond any one entity. This is particularly relevant to complex conditions such as Alzheimer’s disease.
Keywords
- Type
- Chapter
- Information
- Alzheimer's Disease Drug DevelopmentResearch and Development Ecosystem, pp. 449 - 454Publisher: Cambridge University PressPrint publication year: 2022